The 16 most recent market catalysts affecting $ETON, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 24, 2026
Corporate Catalyst
Neutral
Impact 55
Watching Eton Pharmaceuticals; Hearing Zacks HR Investor Buys Stock
The headline indicates that an investor associated with Zacks HR is buying stock in Eton Pharmaceuticals. This is generally viewed as a positive signal, suggesting that an informed…
Aug 17, 2026
Market Technicals
Bearish
Impact 65
Dow Falls Over 100 Points, Records Weekly Loss: Investor Sentiment Weakens, but Fear Index Remains in ‘Greed’ Zone
The filing highlights a divergence in market performance, with the Dow Jones experiencing a weekly loss driven by weak economic data like declining consumer sentiment and retail sa…
Aug 14, 2026
Corporate Catalyst
Bullish
Impact 55
Canaccord Genuity Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $68
Canaccord Genuity analyst Gary Nachman has maintained a 'Buy' rating for Eton Pharmaceuticals and raised the price target from $60 to $68. This action signals increased confidence …
Aug 14, 2026
Corporate Catalyst
Bullish
Impact 65
B. Riley Securities Reiterates Buy on Eton Pharmaceuticals, Raises Price Target to $70
B. Riley Securities analyst Madison El-Saadi reiterated a 'Buy' rating for Eton Pharmaceuticals and substantially raised the price target from $40 to $70. This significant increase…
Aug 14, 2026
Corporate Catalyst
Bullish
Impact 85
Eton Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results and issued FY26 revenue guidance above estimates. Also, HC Wainwright maintained a Buy rating on the stock and raised its price target from $65 to $70.
This headline is a significant positive catalyst for Eton Pharmaceuticals. The combination of strong past performance (Q2 results) and optimistic future projections (FY26 guidance)…
Aug 14, 2026
Corporate Catalyst
Bullish
Impact 55
HC Wainwright & Co. Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $70
HC Wainwright & Co. analyst Swayampakula Ramakanth maintained a 'Buy' rating on Eton Pharmaceuticals and raised the price target from $65 to $70. This analyst upgrade signals incre…
Aug 14, 2026
Corporate Catalyst
Bullish
Impact 95
Why Eton Pharmaceuticals Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket
Eton Pharmaceuticals' shares surged over 22% in pre-market trading due to a significant beat on both Q2 earnings per share and revenue, coupled with an optimistic FY26 revenue guid…
Aug 13, 2026
Corporate Catalyst
Bullish
Impact 92
Eton Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results and issued FY26 revenue guidance above estimates.
This headline represents a major corporate catalyst for Eton Pharmaceuticals. Exceeding Q2 expectations indicates strong operational performance, while issuing FY26 revenue guidanc…
Aug 13, 2026
Corporate Catalyst
Bullish
Impact 95
Eton Pharmaceuticals Q2 Adj. EPS $0.43 Beats $0.10 Estimate, Sales $37.568M Beat $27.119M Estimate
Eton Pharmaceuticals reported a robust Q2, with adjusted EPS of $0.43 significantly beating the $0.10 estimate and sales of $37.568 million surpassing the $27.119 million estimate.…
Aug 13, 2026
Corporate Catalyst
Neutral
Impact 75
Eton Pharmaceuticals FY2026 Revenue expected to be more than $145.000M vs $121.326M Est
Eton Pharmaceuticals has provided an updated revenue outlook for fiscal year 2026, projecting sales to exceed $145 million. This figure is substantially higher than the current ana…
Aug 11, 2026
Corporate Catalyst
Bullish
Impact 60
HC Wainwright & Co. Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $65
HC Wainwright & Co. analyst Swayampakula Ramakanth has maintained a 'Buy' rating on Eton Pharmaceuticals and raised the price target from $57 to $65. This analyst upgrade signals i…
Jul 29, 2026
Corporate Catalyst
Bullish
Impact 65
Eton Pharmaceuticals Submits FDA Prior Approval Supplement For Its New Formulation Of KHINDIVI Oral Solution
Eton Pharmaceuticals has filed a Prior Approval Supplement (PAS) with the FDA to expand the label for its KHINDIVI oral solution to include pediatric patients under five years of a…
Jul 28, 2026
Corporate Catalyst
Bullish
Impact 75
Eton Pharmaceuticals shares are trading higher after Craig-Hallum raised its price target on the stock from $40 to $62.
The upgrade of Eton Pharmaceuticals' price target from $40 to $62 by Craig-Hallum is a strong positive corporate catalyst. This substantial increase suggests that the analyst firm …
Jul 28, 2026
Corporate Catalyst
Bullish
Impact 65
Craig-Hallum Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $62
Craig-Hallum analyst Chase Knickerbocker has maintained a 'Buy' rating on Eton Pharmaceuticals and raised the price target from $40 to $62. This significant increase in the price t…
Jul 17, 2026
Corporate Catalyst
Bullish
Impact 75
Eton Pharmaceuticals shares are trading higher after Canaccord Genuity initiated coverage on the stock with a Buy rating and announced a $60 price target.
The initiation of coverage by Canaccord Genuity with a 'Buy' rating and a $60 price target is a strong positive catalyst for Eton Pharmaceuticals. This action often leads to increa…
Jul 17, 2026
Corporate Catalyst
Neutral
Impact 65
Canaccord Genuity Initiates Coverage On Eton Pharmaceuticals with Buy Rating, Announces Price Target of $60
Canaccord Genuity analyst Gary Nachman initiated coverage on Eton Pharmaceuticals (ETON) with a 'Buy' rating and set a price target of $60. This event is significant as new analyst…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.